Entrada Therapeutics (TRDA) Cash & Equivalents (2020 - 2026)

Entrada Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $76.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 12.69% year-over-year to $76.4 million; the TTM figure through Mar 2026 stood at $76.4 million (up 12.69% YoY), while the FY2025 annual figure was $90.4 million, down 10.69% from the prior year.
• Cash & Equivalents was $76.4 million for Q1 2026 at Entrada Therapeutics, down from $90.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $227.6 million in Q1 2023 to a low of $45.2 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $90.2 million across 5 years, with a median of $78.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 84.49% in 2022, then soared 168.96% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $45.2 million in 2022, then surged by 49.7% to $67.6 million in 2023, then surged by 49.72% to $101.2 million in 2024, then retreated by 10.69% to $90.4 million in 2025, then fell by 15.43% to $76.4 million in 2026.
• The last three Cash & Equivalents figures came in at $76.4 million (Q1 2026), $90.4 million (Q4 2025), and $93.3 million (Q3 2025), per Business Quant data.